Preventive Antibiotics in Stroke Study

Conditions

Stroke, infection Circulatory System Stroke, not specified as haemorrhage or infarction

Twan J. van Velzen, Jeffrey Stolp, Willeke F. Westendorp, Yvo B.W.E.M. Roos, Diederik van de Beek et al. (6 authors)

Journal of Clinical Medicine2022-12-081 citations

Prevalence, predictors and outcome of carotid stenosis: a sub study in the Preventive Antibiotics in Stroke Study (PASS).

van Velzen TJ, Kuhrij LS, Westendorp WF, van de Beek D, Nederkoorn PJ.

2021-01-1216 citations

10.1186/s12883-020-02032-4

Association Between Low Blood Pressure and Clinical Outcomes in Patients With Acute Ischemic Stroke

Merelijne A. Verschoof, Adrien E.D. Groot, Jan‐Dirk Vermeij, Willeke F. Westendorp, Sophie A. van den Berg et al. (8 authors)

Stroke2019-10-3121 citations

10.1161/strokeaha.119.027336

Continuation or Discontinuation of Anticoagulation in the Early Phase After Acute Ischemic Stroke

Adrien E.D. Groot, Jan‐Dirk Vermeij, Willeke F. Westendorp, Paul J. Nederkoorn, Diederik van de Beek et al. (6 authors)

Stroke2018-05-2912 citations

10.1161/strokeaha.118.021514

The Preventive Antibiotics in Stroke Study (PASS): a pragmatic randomised open-label masked endpoint clinical trial.

Westendorp WF, Vermeij JD, Zock E, Hooijenga IJ, Kruyt ND, Bosboom HJ, Kwa VI, Weisfelt M, Remmers MJ, ten Houten R, Schreuder AH, Vermeer SE, van Dijk EJ, Dippel DW, Dijkgraaf MG, Spanjaard L, Vermeulen M, van der Poll T, Prins JM, Vermeij FH, Roos YB, Kleyweg RP, Kerkhoff H, Brouwer MC, Zwinderman AH, van de Beek D, Nederkoorn PJ, PASS investigators.

2015-01-20233 citations

10.1016/s0140-6736(14)62456-9

Update of the Preventive Antibiotics in Stroke Study (PASS): statistical analysis plan.

Westendorp WF, Vermeij JD, Dippel DW, Dijkgraaf MG, van der Poll T, Prins JM, Vermeij FH, Roos YB, Brouwer MC, Zwinderman AH, van de Beek D, Nederkoorn PJ.

2014-10-015 citations

10.1186/1745-6215-15-382

Update on the Preventive Antibiotics in Stroke Study (PASS): a randomised controlled phase 3 clinical trial

Willeke F. Westendorp, Jan‐Dirk Vermeij, Nan van Geloven, Diederik W.J. Dippel, Marcel G. W. Dijkgraaf et al. (11 authors)

Trials2014-04-216 citations

10.1186/1745-6215-15-133

Interventions

Our intervention group will be treated with optimal medical care and ceftriaxone 2000 mg, intravenously, 1 time daily, for 4 days. The control group will receive the optimal medical care without ceftr

the primary outcome will then be assessed in a structured interview by telephone.

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Aged greater than or equal to 18 years, either sex 2. Stroke (ischaemic and haemorrhagic) 3. Any measurable neurological deficit defined as National Institutes of Health Stroke Scale (NIHSS) greater than 1 4. Stroke onset less than 24 hours 5. Admission

Exclusion criteria

Exclusion criteria: 1. Symptoms or signs of infection on admission requiring antibiotic therapy 2. Use of antibiotics less than 24 hours before admission 3. Pregnancy 4. Hypersensitivity for cephalosporin 5. Previous anaphylaxis for penicillin or penicillin-derivates 6. Subarachnoid haemorrhage

Design outcomes

Primary

Measure	Time frame
Functional health at 3-month follow-up, as assessed by the modified Rankin scale (mRS) dichotomised as a favorable outcome (mRS 0 - 2) or an unfavorable outcome (mRS 3 - 6)	—

Secondary

Measure	Time frame
1. Death rate at discharge and 3 months 2. Infection rate during hospital admission 3. Length of hospital admission 4. Volume of post-stroke care 5. Use of antibiotics during the 3 months follow-up 6. Functional health using the full ordinal scoring range of the mRS 7. Quality adjusted life years (QALYs) 8. Costs	—

Countries

Netherlands

Outcome results

None listed